Guardant Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Guardant Health, Inc. on December 11, 2020. The filing reports on corporate governance changes, specifically the appointment of a new Chief Financial Officer (CFO) and the resignation of the previous officer, effective in early 2021.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on executive compensation and employment terms.
Material Changes and Executive Compensation
The primary material change is the leadership transition in the finance department:
- Appointment of Michael Bell: The Board appointed Michael Bell as CFO, effective January 5, 2021. Mr. Bell brings extensive experience from CareDx, Metabiota, Singulex, and Novartis.
- Compensation Package for Mr. Bell:
- Annual Base Salary: $450,000.
- Target Bonus: 50% of annual base salary.
- Signing Bonus: $500,000 (subject to clawback if employment ends voluntarily before 24 months).
- Equity Grants:
- Restricted Stock Units (RSUs): Valued at approximately $2,000,000, vesting ratably over four years.
- Stock Options: Valued at approximately $2,000,000, vesting 25% on the first anniversary and the remainder monthly over the subsequent three years.
- Performance Stock Units (PSUs): Valued at approximately $1,000,000, vesting upon achievement of specific objectives.
- Resignation of Derek Bertocci: Mr. Bertocci resigned as an officer on December 4, 2020. He remains an employee to assist with the transition until approximately March 5, 2021.
- Transition Compensation for Mr. Bertocci: He will be paid $22 per hour for transition services. His outstanding stock options and RSUs will continue to vest during this period.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or management commentary on business performance. The primary risk disclosed relates to the execution of the transition between the outgoing and incoming CFOs, which is being managed through a structured transition period for the former officer.
Key Facts for Investor Verification
- Verify the effective start date of Michael Bell as CFO (January 5, 2021).
- Confirm the total value of the equity package granted to Mr. Bell ($5,000,000 in RSUs, Options, and PSUs).
- Note the clawback provision on the $500,000 signing bonus if Mr. Bell leaves voluntarily within 24 months.
- Review the transition timeline for Derek Bertocci, expected to conclude on March 5, 2021.
- Check the attached Offer Letter (Exhibit 10.1) and Employment Letter (Exhibit 10.2) for full legal terms.